Last Updated: 2026

SD BioSensor

Rank#7069

Market Cap591.44M

CountrySouth Korea

Summary

SD BioSensor Inc., an in-vitro diagnostic company, provides point-of-care diagnostic solutions in South Korea and internationally. The company's products include STANDARD Q, which provides various rapid test parameters comprising COVID-19 products and other parameters; STANDARD F, a multi-parametric and random accessible FIA system that provides diagnostic results to the laboratories; and STANDARD E, an enzyme linked immunosorbent assay for mass screening tests. Its products also include STANDARD M, a point-of-care MDx system for clinical decision making near-the-patient, which include analyzers, assay menus, qPCR reagents, and NA extraction kits; procell Dx, an in vitro diagnostic products for the diagnosis of infectious disease, such as tuberculosis and SARS-CoV-2, and for checking the immune status of individuals through the interferon gamma release assay; and blood glucose meters. The company was founded in 2010 and is headquartered in Suwon, South Korea.

History

Founded in 2019, SD BioSensor has grown to become a leader in providing medical imaging technologies. Our innovative systems combine visual imaging and computer-aided detection (CAD) algorithms to help medical professionals and researchers improve patient care and outcomes.

Mission

Our mission is to help create a healthier, safer world by merging the most advanced medical technologies with practical, insightful industry experience.

Vision

We envision a world where everyone has access to advanced medical technologies that enable earlier diagnosis, improved treatments, and better outcomes for patients.

References

https://en.wikipedia.org/wiki/Biosensors_International

https://in.investing.com/equities/sd-biosensor

https://finance.yahoo.com/quote/137310.KS/profile?p=137310.KS

https://www.crunchbase.com/organization/sd-biosensor

https://companiesmarketcap.com/

https://www.sdbiosensor.com

Leadership team

Hyo Keun Lee (Vice Chairman & CEO)

Chul-Gyu Oh (CFO & Director)

Tae Young Heo (Pres & CEO)

Products / Services

Biotechnology, Health Care, Medical Device, Pharmaceutical

Number of Employees

500 - 1000

Address

Suwon, Ch'ungch'ong-namdo, South Korea

Established

2010-01-01

Net Income

$1B – $20B

Revenue

$1B+

Traded as

137310.KS

Website

https://www.sdbiosensor.com

Social Media

Last Updated: 2026

SD BioSensor

Rank#7069

Market Cap591.44M

CountrySouth Korea

Summary

History

Mission

Our mission is to help create a healthier, safer world by merging the most advanced medical technologies with practical, insightful industry experience.

Vision

We envision a world where everyone has access to advanced medical technologies that enable earlier diagnosis, improved treatments, and better outcomes for patients.

References

https://en.wikipedia.org/wiki/Biosensors_International

https://in.investing.com/equities/sd-biosensor

https://finance.yahoo.com/quote/137310.KS/profile?p=137310.KS

https://www.crunchbase.com/organization/sd-biosensor

https://companiesmarketcap.com/

https://www.sdbiosensor.com

Leadership team

Hyo Keun Lee (Vice Chairman & CEO)

Chul-Gyu Oh (CFO & Director)

Tae Young Heo (Pres & CEO)

Products / Services